Analysis of angiogenic profiles by estimation of tumor blood flow with colored dye extraction microspheres after antiangiogenic therapy

Oncology Reports

Volumn 10, Issue 5, 2003, Pages 1127-1131

  Iwamaru, Arifumi ^a,b   Watanabe, Masazumi ^a   Ohtsuka, Takashi ^a   Horinouchi, Hirohisa ^a   Kobayashi, Koichi ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b National Seiransou Hospital   (Japan)

Author keywords

Angiogenic profiles; Antiangiogenic therapy; Colored dye extraction microspheres; Combination therapy; TNP 470; Tumor blood flow

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC ANTIBIOTIC; COLORING AGENT; CYCLOHEXANE DERIVATIVE; FUMAGILLOL CHLOROACETYLCARBAMATE; MICROSPHERE; O-(CHLOROACETYLCARBAMOYL)FUMAGILLOL; SESQUITERPENE;

ANIMAL; ARTICLE; ASCITES; CANCER TRANSPLANTATION; DISEASE MODEL; EXPERIMENTAL NEOPLASM; LIVER CELL CARCINOMA; MALE; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); RAT; SPECTROPHOTOMETRY;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ASCITES; CARCINOMA, HEPATOCELLULAR; COLORING AGENTS; CYCLOHEXANES; DISEASE MODELS, ANIMAL; MALE; MICROSPHERES; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; RATS; SESQUITERPENES; SPECTROPHOTOMETRY;

EID: 2142687617     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.10.5.1127     Document Type: Article

References (23)

1. Jain RK: The next frontier of molecular medicine: delivery of therapeutics. Nat Med 6: 655-657, 1998.
2. Jain RK: Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 9: 987-989, 2001.
3. Ma J, Pulfer S, Li S, Chu J, Reed K and Gallo JM: Pharmacodynamic- mediated reduction of temozolomide tumor concentrations by the angiogenesis inhibitor TNP-470. Cancer Res 61: 5401-5498, 2001.
4. Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O'Reilly MS and Folkman J: Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60: 1878-1886, 2001.
5. Ferrara N and Davis-Smith T: The biology of vascular endothelial growth factor. Endocr Rev 18: 4-25, 1997. (Pubitemid 27076453)
6. Folkman J: Angiogenesis and angiogenesis inhibition: an overview. EXS 79: 1-8, 1997.
7. Izumi Y, Xu L, Tomaso E, Fukumura D and Jain RK: Herceptin acts as an anti-angiogenic cocktail. Nature 416: 279-280, 2002. (Pubitemid 34260234)
8. Carmeliet P, Dor Y, Herbert JM, Fukumura D, Brusselmans K, Dewerchin M, Neeman M, Bono F, Abramovitch R, Maxwell P, Koch CJ, Ratliffe P, Moons L, Jain RK, Collen D and Keshet E: Role of HIF-1 α in hypoxia-mediated apoptosis. Cell proliferation and tumor angiogenesis. Nature 394: 485-490, 1998. (Pubitemid 28373960)
9. Ferrara N and Alitalo K: Clinical applications of angiogenic growth factors and their inhibitors. Nat Med 5: 1359-1364, 1999.
10. Iwamaru A, Watanabe M, Yu S, Ohtsuka T, Horinouchi H and Kobayashi K: Measurement of tumor blood flow using colored dye extraction microspheres in two rat tumor models. Int J Oncol 18: 227-232, 2001.
11. Hori K, Zhang Q-H, Li H-C and Saito S: Variation of growth rate of a rat tumor during a light-dark cycle: correlation with circadian fluctuations in tumor blood flow. Br J Cancer 71: 1163-1168, 1995.
12. Kato H, Ishihara H, Kawarada Y, Furuya M, Kondo S, Kato H and Yoshiki T: Anti-angiogenic treatment for peritoneal dissemination of pancreas adenocarcinoma: a study using TNP-470. Jpn J Cancer Res 92: 67-73, 2001. (Pubitemid 32175480)
13. Niwano M, Araii S, Mori A, Ishigami S, Harada T, Mise M, Furutani M, Fujioka M and Imamura M: Inhibition of tumor growth and microvascular angiogenesis by the potent angiogenesis inhibitor, TNP-470, in rats. Surg Today 28: 915-922, 1999.
14. Hale S, Alker K and Klone R: Evaluation of nonradioactive, colored microspheres for measurement of regional myocardial blood flow in dogs. Circulation 78: 428-434, 1998.
15. Kowallik P, Schulz R, Guth BD, Schade A, Paffhausen W, Gross R and Heusch G: Measurement of regional myocardial blood flow with multiple colored microspheres. Circulation 83: 974-982, 1991.
16. Häkkinen JP, Miller MW, Smith AH and Knight DR: Measurement of organ blood flow with coloured microspheres in the rat. Cardiovasc Res 29: 74-79, 1995.
17. Hori K, Sato S, Takahashi H, Maeda H and Sato Y: Tumor-selective blood flow decrease induced by an angiotensin converting enzyme inhibitor, temocapril hydrochloride. Jpn J Cancer Res 91: 261-269, 2000. (Pubitemid 30130758)
18. Chaplin DJ and Horsman MR: Tumor blood flow changes included by chemical midifiers of radiation response. Int J Radiat Oncol 22: 59-462, 1992.
19. Dewhirst MW, Ong ET, Braun RD, Smith B, Klitzman B, Evans SM and Wilson D: Quantification of longitudinal pO2 gradients in window chamber tumors: impact on tumor hypoxia. Br J Cancer 79: 1717-1722, 1999. (Pubitemid 29132294)
20. Patel JD, Krug LM, Crapanzano J, et al: Clinical characteristics and outcomes of patients with advanced non-small cell lung cancer treated with trastuzumab plus either weekly docetaxel or paclitaxel. ASCO, 1218, 2002.
21. Murata R, Nishimura Y and Hiraoka M: An antiangiogenic agent (TNP-470) inhibited reoxygenation during fractionated radiotherapy of murine mammary carcinoma. Int J Radiat Oncol Biol Phys 37: 1107-1113, 1997. (Pubitemid 27230036)
22. Farinelle S, Malbonne H, Chaboteaux C, Decaestecker C, Dedecker R, Gras T, Darro F, Fontaine J, Atassi G and Kiss R: Characterization of TNP-470-induced modifications to cell functions in HUVEC and cancer cells. J Pharmacol Toxicol 43: 15-24, 2000.
23. D'Amico T, Aloia T, Moore HM, Conlon D, Herndon J II, Kinch SM and Harpole HD Jr: Predicting the sites of metastases from lung cancer using molecular biologic markers. Ann Thorac Surg 72: 1144-1148, 2001. (Pubitemid 32937993)